Rosuvastatin Intermediates ZD9 CAS:289042-10-0

The synthesis of rosuvastatin involves a series of organic reactions, starting with simple starting materials and progressing through a series of intermediate compounds. ZD9 intermediates are formed through a series of carefully controlled chemical reactions, including oxidation, reduction, and coupling reactions. The ZD9 intermediates are characterized by the presence of a pyrimidine ring, which is a key structural feature of rosuvastatin. The pyrimidine ring is a six-membered heterocyclic ring with nitrogen atoms at positions 1, 3, and 5. This ring system is a common structural motif in many biologically active compounds and is responsible for some of the therapeutic effects of rosuvastatin. In addition to the pyrimidine ring, the ZD9 intermediates also contain a fluorophenyl group, an isopropyl group, and an amino group. These substituents are strategically placed on the molecule to impart specific physical and chemical properties, such as improved solubility, stability, and bioavailability. The synthesis of ZD9 intermediates requires careful control of reaction conditions, including temperature, pressure, and the use of catalysts. The reactions must be carefully monitored to ensure the desired products are obtained with high purity and yield. Once the ZD9 intermediates are synthesized, they undergo further chemical modifications to eventually produce rosuvastatin. These modifications include the introduction of additional substituents and the optimization of the molecule's overall structure for improved biological activity. The development of efficient and cost-effective synthetic routes for rosuvastatin intermediates ZD9 is of great importance to the pharmaceutical industry. It allows for the规模化 production of rosuvastatin, ensuring a consistent supply of this essential medication for the treatment of cardiovascular disease. In conclusion, rosuvastatin intermediates ZD9 are crucial components in the synthesis of rosuvastatin, a widely used statin medication. The synthesis of these intermediates involves a series of carefully controlled chemical reactions, and their use in the pharmaceutical manufacturing process is essential for ensuring the availability of rosuvastatin for the treatment of cardiovascular disease.